These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36228766)

  • 1. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
    Argirò A; Zampieri M; Dei LL; Ferrantini C; Marchi A; Tomberli A; Baldini K; Cappelli F; Favilli S; Passantino S; Zocchi C; Tassetti L; Gabriele M; Maurizi N; Marchionni N; Coppini R; Olivotto I
    Int J Cardiol; 2023 Jan; 370():271-278. PubMed ID: 36228766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.
    Olivotto I; Camici PG; Merlini PA; Rapezzi C; Patten M; Climent V; Sinagra G; Tomberli B; Marin F; Ehlermann P; Maier LS; Fornaro A; Jacobshagen C; Ganau A; Moretti L; Hernandez Madrid A; Coppini R; Reggiardo G; Poggesi C; Fattirolli F; Belardinelli L; Gensini G; Mugelli A
    Circ Heart Fail; 2018 Jan; 11(1):e004124. PubMed ID: 29321131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.
    Ferrantini C; Pioner JM; Mazzoni L; Gentile F; Tosi B; Rossi A; Belardinelli L; Tesi C; Palandri C; Matucci R; Cerbai E; Olivotto I; Poggesi C; Mugelli A; Coppini R
    Br J Pharmacol; 2018 Jul; 175(13):2635-2652. PubMed ID: 29579779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
    Ling H; Packard KA; Burns TL; Hilleman DE
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
    Coppini R; Ferrantini C; Yao L; Fan P; Del Lungo M; Stillitano F; Sartiani L; Tosi B; Suffredini S; Tesi C; Yacoub M; Olivotto I; Belardinelli L; Poggesi C; Cerbai E; Mugelli A
    Circulation; 2013 Feb; 127(5):575-84. PubMed ID: 23271797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
    Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
    Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
    Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.
    Flenner F; Friedrich FW; Ungeheuer N; Christ T; Geertz B; Reischmann S; Wagner S; Stathopoulou K; Söhren KD; Weinberger F; Schwedhelm E; Cuello F; Maier LS; Eschenhagen T; Carrier L
    Cardiovasc Res; 2016 Jan; 109(1):90-102. PubMed ID: 26531128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine].
    Tomberli B; Girolami F; Coppini R; Ferrantini C; Rossi A; Cecchi F; Olivotto I
    G Ital Cardiol (Rome); 2012 Apr; 13(4):297-303. PubMed ID: 22495647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.
    Figueredo VM; Pressman GS; Romero-Corral A; Murdock E; Holderbach P; Morris DL
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):168-72. PubMed ID: 20924097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy.
    Coleman JA; Doste R; Beltrami M; Argirò A; Coppini R; Olivotto I; Raman B; Bueno-Orovio A
    Front Pharmacol; 2024; 15():1379236. PubMed ID: 38659580
    [No Abstract]   [Full Text] [Related]  

  • 16. Ranolazine for chronic stable angina.
    Nash DT; Nash SD
    Lancet; 2008 Oct; 372(9646):1335-41. PubMed ID: 18929905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study.
    Zweiker R; Aichinger J; Metzler B; Lang I; Wallner E; Delle-Karth G
    Wien Klin Wochenschr; 2019 Apr; 131(7-8):165-173. PubMed ID: 30963332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.